Wells Fargo initiated coverage of Viridian Therapeutics (VRDN) with an Overweight rating and $46 price target. The firm thinks the recent pullback off its highs offers a nice setup into Viridian’s remaining 2023 catalysts. Wells views Viridian as a lower clinical risk story and believes its current data supports a differentiated profile relative to Horizon Therapeutics’ (HZNP) Tepezza.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- TipRanks ‘Perfect 10’ List: 2 Top-Rated Stocks Potentially Undervalued by ~90%
- Viridian Therapeutics CEO buys $101K in common stock
- Viridian Therapeutics appoints Casciano as Chief Commercial officer
- Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)